Abstract 237P
Background
There is paucity of data of role of PARP inhibitors (PARPi) in BRCA mutation (gBRCAm) positive platinum resistant ovarian cancer (OC) disease. We report here analysis of outcome of PARPi treatment in patients including those with platinum resistant disease.
Methods
In this study, we analyzed efficacy of PARPi in all consecutive patients of OC with gBRCAm who received the drug. The drug was procured through compassionate program.
Results
Between July 1, 2015 and June 30, 2019, 28 patients received PARPi. At the time of data censoring (June 30, 2019), 6 (21.4%) patients are still on treatment. 5 patient received Talazoparib and 23 Olaparib. Median age is 54.5 years (range 39-75). BRCAm 1 positive patients were 20. Median number of previous lines of chemotherapy received were 3 (range 1-6). 7 platinum sensitive patients received the drug as maintenance (3 in complete response [CR] and 4 in partial response [PR]) while 21 had platinum resistant progressive disease. Overall response rate (ORR) was 82% with CR as the best response in 5 which also includes 3 patients who received the drug while in CR and maintained it. With the median treatment duration (mTD) of 14.14 months (95%CI 8.43-23.33), 71.4 % patients eventually progressed. The median follow up was 15.3 months (range 4- 42.6 months). The median overall survival (OS) was 32.9 months (95% CI 13.03 NR) The below table describes results of 21 platinum resistant patients. With the mTD of 10.4 months (95%CI 8.17 23.33), 86 % patients had progressed. Three (14%) platinum resistant patients are still on treatment with the treatment duration (TD) of 5.47, 32.9 and 37 months.
Table: 237P
Response | N (%) |
---|---|
ORR | 16 (76) |
CR | 1 (4.7) |
PR | 15 (71.4) |
PD | 5 (24) |
Median OS in months (95% CI) | 28.8 (9.6 NR) |
Progression free survival was not calculated as disease assessment was not done at defined time point. The TD was taken as the surrogate marker for efficacy. Grade ≥3 side effects were documented in 33% patients (anemia 23.5%, thrombocytopenia 17.6%, fatigue 25%).
Conclusions
This study suggests that PARPi is a viable treatment option in patients of platinum resistant OC with gBRCAm. This should be further evaluated in randomized clinical controlled trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amit Agarwal.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients
Presenter: Andree Kurniawan
Session: Poster display session
Resources:
Abstract
438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients
Presenter: Yi Long Toh
Session: Poster display session
Resources:
Abstract
440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
442P - Relationship between QOL and support elderly patients with permanent colostomies
Presenter: Yukiko Orii
Session: Poster display session
Resources:
Abstract
443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study
Presenter: Saori Koshimoto
Session: Poster display session
Resources:
Abstract
444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine
Presenter: Takayuki Tsuchiya
Session: Poster display session
Resources:
Abstract
445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments
Presenter: Sang Bo Oh
Session: Poster display session
Resources:
Abstract
446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation
Presenter: Sharif Ahmed
Session: Poster display session
Resources:
Abstract